ECSP014068A - Procedimiento para regular la angiogenesis utilizando proteina ryk - Google Patents
Procedimiento para regular la angiogenesis utilizando proteina rykInfo
- Publication number
- ECSP014068A ECSP014068A EC2001004068A ECSP014068A ECSP014068A EC SP014068 A ECSP014068 A EC SP014068A EC 2001004068 A EC2001004068 A EC 2001004068A EC SP014068 A ECSP014068 A EC SP014068A EC SP014068 A ECSP014068 A EC SP014068A
- Authority
- EC
- Ecuador
- Prior art keywords
- ryk
- angiogenesis
- diseases
- procedure
- proteins
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000006884 regulation of angiogenesis Effects 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56878300A | 2000-05-10 | 2000-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP014068A true ECSP014068A (es) | 2002-02-25 |
Family
ID=24272718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2001004068A ECSP014068A (es) | 2000-05-10 | 2001-05-09 | Procedimiento para regular la angiogenesis utilizando proteina ryk |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1287121A2 (enExample) |
| JP (1) | JP2004527206A (enExample) |
| AR (1) | AR028424A1 (enExample) |
| AU (1) | AU2001261343A1 (enExample) |
| CA (1) | CA2408349A1 (enExample) |
| CO (1) | CO5300464A1 (enExample) |
| DO (1) | DOP2001000164A (enExample) |
| EC (1) | ECSP014068A (enExample) |
| GT (1) | GT200100079A (enExample) |
| PE (1) | PE20011218A1 (enExample) |
| SV (1) | SV2002000442A (enExample) |
| UY (1) | UY26696A1 (enExample) |
| WO (1) | WO2001085789A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501523B2 (en) | 2014-07-18 | 2019-12-10 | Sanofi | IL-8 level based method of predicting the outcome of colon cancer treatment |
| US11033606B2 (en) | 2011-04-26 | 2021-06-15 | Sanofi | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516608A (ja) * | 2002-02-06 | 2005-06-09 | デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング | エネルギー恒常性の調節に関与するキナーゼ |
| TW202315894A (zh) * | 2021-08-18 | 2023-04-16 | 美國加利福尼亞大學董事會 | 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107472A (en) * | 1992-05-11 | 2000-08-22 | Ludwig Institute For Cancer Research | Receptor-type tyrosine kinase-like molecules |
| AU4606196A (en) * | 1994-12-23 | 1996-07-19 | Ludwig Institute For Cancer Research | Assay, receptor proteins and ligands |
| EP1084245B1 (en) * | 1998-06-11 | 2006-03-29 | AstraZeneca AB | Human receptor tyrosine kinase |
| WO2000024415A2 (en) * | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
-
2001
- 2001-05-07 GT GT200100079A patent/GT200100079A/es unknown
- 2001-05-07 AR ARP010102149A patent/AR028424A1/es not_active Application Discontinuation
- 2001-05-08 UY UY26696A patent/UY26696A1/es not_active Application Discontinuation
- 2001-05-09 CO CO01036462A patent/CO5300464A1/es unknown
- 2001-05-09 JP JP2001582388A patent/JP2004527206A/ja active Pending
- 2001-05-09 EC EC2001004068A patent/ECSP014068A/es unknown
- 2001-05-09 WO PCT/US2001/015043 patent/WO2001085789A2/en not_active Ceased
- 2001-05-09 SV SV2001000442A patent/SV2002000442A/es not_active Application Discontinuation
- 2001-05-09 EP EP01935233A patent/EP1287121A2/en not_active Withdrawn
- 2001-05-09 AU AU2001261343A patent/AU2001261343A1/en not_active Abandoned
- 2001-05-09 CA CA002408349A patent/CA2408349A1/en not_active Abandoned
- 2001-05-10 DO DO2001000164A patent/DOP2001000164A/es unknown
- 2001-05-10 PE PE2001000417A patent/PE20011218A1/es not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033606B2 (en) | 2011-04-26 | 2021-06-15 | Sanofi | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) |
| US10501523B2 (en) | 2014-07-18 | 2019-12-10 | Sanofi | IL-8 level based method of predicting the outcome of colon cancer treatment |
| US11208461B2 (en) | 2014-07-18 | 2021-12-28 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20011218A1 (es) | 2002-02-01 |
| SV2002000442A (es) | 2002-07-03 |
| CA2408349A1 (en) | 2001-11-15 |
| EP1287121A2 (en) | 2003-03-05 |
| AU2001261343A1 (en) | 2001-11-20 |
| GT200100079A (es) | 2001-12-31 |
| UY26696A1 (es) | 2001-12-28 |
| DOP2001000164A (es) | 2002-05-15 |
| WO2001085789A2 (en) | 2001-11-15 |
| AR028424A1 (es) | 2003-05-07 |
| JP2004527206A (ja) | 2004-09-09 |
| WO2001085789A3 (en) | 2002-05-16 |
| CO5300464A1 (es) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE290401T1 (de) | Topisch anwendbare mittel gegen nagelpilzerkrankungen | |
| CY1107248T1 (el) | Συντηγμενες πρωτεϊνες | |
| BR9714363A (pt) | Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas | |
| IL117645A (en) | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration | |
| TR200101307T2 (tr) | Antranilik asit amidler ve ilaç olarak kullanılmaları. | |
| ATE263571T1 (de) | Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen | |
| AR012193A1 (es) | Nuevas combinaciones terapeuticas | |
| MXPA04005204A (es) | Derivados de hidrazonipirazol y su uso como terpapeuticos. | |
| DE60031016D1 (de) | Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen | |
| DK1343472T3 (da) | Thixotropisk næsespray | |
| ECSP014068A (es) | Procedimiento para regular la angiogenesis utilizando proteina ryk | |
| ITRM970238A0 (it) | Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella terapia di patologie corneali e congiuntivali | |
| ES2186576A1 (es) | Acido 2-hidroxioleico para utilizar como medicamento. | |
| MX9701996A (es) | Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno. | |
| ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
| DE60107444D1 (de) | Verwendung einer pollenextrakt-enthaltenden verbindung zur behandlung von ödemen | |
| DOP2001000141A (es) | Proteina actuando como un modulador angiogenico | |
| ATE302000T1 (de) | Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen | |
| IT1320192B1 (it) | Composizione terapeutica per la cura della psoriasi. | |
| SV2002000362A (es) | Proteinas que tienen una actividad moduladora de angiogenesis ref.msb-7265-sv | |
| ATE374048T1 (de) | Verwendung von matrixprotein für gesteuerte geweberegenerationen | |
| SE9904863D0 (sv) | New use | |
| AR011907A1 (es) | UTILIZACIoN DEL ACIDO 4-(2,2-DIMETILPROPANOL)BUTANOICO (PIVAGABIN)PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE FORMAS DE ANSIEDADDEPRESIVA. | |
| WO2001074852A3 (en) | Protein having activity as an angiogenesis modulator | |
| MX2024014811A (es) | Composiciones de menaquinol pegilado y metodos de tratamiento |